5-溴-2-乙基苯甲酸 | 439937-55-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-溴-2-乙基苯甲酸
• 英文名称: 5-Brom-2-ethyl-benzoesaeure
• 英文别名: 2-ethyl-5-bromobenzoic acid；5-Bromo-2-ethylbenzoic acid
• CAS: 439937-55-0
• 化学式: C₉H₉BrO₂
• 分子量: 229.073
• InChiKey: RJJFAACSONNSDX-UHFFFAOYSA-N

物化性质

• 熔点：
  88-90 °C(Solv: ligroine (8032-32-4))
• 沸点：
  318.3±30.0 °C(Predicted)
• 密度：
  1.517±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-溴-2-乙基苯甲酸 在 草酰氯 、 potassium carbonate 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 反应 23.58h， 生成 C₁₀H₁₂BrNO₂
  参考文献：
  名称：

  铁/光氧化还原双催化酰基氮烯基 C-O 键形成苯酞

  摘要：

  本文描述了铁/光氧化还原双催化酰基氮烯的形成以及酰基氮烯在构建各种 C-O 键中对苯酞的应用。开发的反应从N -methoxyl-2-alkylbenzamides 开始。机理调查表明，该反应涉及基于铁氮烯的氢原子提取 (HAA)、自由基-极性交叉和O-亲核 S N 1。值得注意的是，未观察到以前出版物中经常报道的自由基反弹。该反应代表了基于酰基氮烯的苯酞合成的第一个例子。此外，它还作为合成3-丁基苯酞（NBP）、沙利度胺、Pomalyst和Otezia等市售药物的补充剂。

  DOI：

  10.1039/d2cc04917a
• 作为产物：
  描述：

  2-乙基苯甲腈 在 溴 作用下， 生成 5-溴-2-乙基苯甲酸
  参考文献：
  名称：

  AUTERHOFF; FRAUENDORF; LIESENKLAS, Archiv der Pharmazie, 1962, vol. 295 /67, p. 833 - 846

  摘要：

  DOI：

文献信息

• Substituted 6-azabenzimidazole compounds
  申请人：Gilead Sciences, Inc.

  公开号：US11203591B2

  公开（公告）日：2021-12-21

  The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

  本公开一般涉及某些 6-氮杂苯并咪唑化合物、包含所述化合物的药物组合物以及制造和使用所述化合物和药物组合物的方法。本文公开的化合物和组合物可用于治疗或预防可被造血祖细胞激酶 1（HPK1）抑制剂改变的疾病、失调或感染，如 HBV、HIV、癌症和/或过度增殖性疾病。
• Design, Synthesis, and Structure−Activity Relationship of a Novel Series of 2-Aryl 5-(4-Oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 Entry Inhibitors
  作者：Alan R. Katritzky、Srinivasa R. Tala、Hong Lu、Anatoliy V. Vakulenko、Qi-Yin Chen、Jothilingam Sivapackiam、Keyur Pandya、Shibo Jiang、Asim K. Debnath

  DOI：10.1021/jm900450n

  日期：2009.12.10

  We previously identified two small molecules targeting the HIV-1 gp41, N-(4-carboxy-3-hydroxy)phenyl-2,5-dimethylpyrrole 12 (NB-2) and N-(3-carboxy-4-chloro)phenylpyrrole 13 (NB-64), that inhibit HIV-1 infection at low micromolar levels. Oil the basis of molecular docking analysis, we designed a series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans. Compared with 12 and 13, these compounds have bigger molecular size (437-515 Da) and could occupy more space in the deep hydrophobic pocket oil the gp41 NHR trimer. Fifteen 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans (11a-o) were synthesized by Suzuki-Miyaura cross-coupling followed by a Knoevenagel condensation and tested for their anti-HIV-1 activity and cytotoxicity on MT-2 cells. We found that all 15 compounds had improved anti-HIV-1 activity and 3 of them (11a, 11b, and 11d) exhibited inhibitory activity against replication of HIB-1(IIIB) and 94UG103 at < 100 nM range, more than 20-fold more potent than 12 and 13, suggesting that these Compounds can serve as leads for development of novel small molecule HIV fusion inhibitors.
• SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS
  申请人：GILEAD SCIENCES, INC.

  公开号：EP3873903A1

  公开（公告）日：2021-09-08
• SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20210115037A1

  公开（公告）日：2021-04-22

  The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
• AUTERHOFF; FRAUENDORF; LIESENKLAS, Archiv der Pharmazie, 1962, vol. 295 /67, p. 833 - 846
  作者：AUTERHOFF、FRAUENDORF、LIESENKLAS、SCHWANDT

  DOI：——

  日期：——